Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study
Journal of Clinical Oncology · 10.01.2025 · 43 (2) · 180-188
DOI: 10.1200/jco.24.00171 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2025. Verfasst von Christine Brunner und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Breast Neoplasms, Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents, Bone Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Medication-related osteonecrosis of the jaw (MRONJ) is one of the most important toxicities of antiresorptive therapy, which is standard practice for patients with breast cancer and bone metastases. However, the population-based incidence of MRONJ is not well established. We therefore performed a retrospective multicenter study to assess the incidence for a whole Austrian federal state (Tyrol). MATERIALS AND METHODS This retrospective multicenter study was conducted between 2000 and 2020 at all nine breast centers across Tyrol, Austria. Using the cancer registry, the total Tyrolean population was screened for all patients with breast cancer. All patients with breast cancer and bone metastases receiving antiresorptive therapy were finally included in the study. RESULTS From 8,860 patients initially screened, 639 individuals were eligible and included in our study. Patients received antiresorptive therapy once per month without de-escalation of therapy. MRONJ was diagnosed in 56 (8.8%, 95% CI, 6.6 to 11.0) patients. The incidence of MRONJ was 11.6% (95% CI, 8.0 to 15.3) in individuals treated with denosumab only, 2.8% (95% CI, 0.7 to 4.8) in those treated with bisphosphonates only, and 16.3% (95% CI, 8.8 to 23.9) in the group receiving bisphosphonates followed by denosumab. Individuals developed MRONJ significantly earlier when treated with denosumab. Time to MRONJ after treatment initiation was 4.6 years for individuals treated with denosumab only, 5.1 years for individuals treated with bisphosphonates only, and 8.4 years for individuals treated with both consecutively. CONCLUSION MRONJ incidence in breast cancer patients with bone metastases was found to be considerably higher, especially for patients receiving denosumab, when compared with available data in the literature. Additionally, patients treated with denosumab developed MRONJ significantly earlier.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Public Health, Health Services Research and Health Technology Assessment, Medical Decision Making and Health Technology Assessment, Institute of Public Health, UMIT TIROL-University for Health Sciences and…
- Department of Cranio-Maxillofacial and Oral Surgery, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Visceral, Transplant and Thoracic Surgery (VTT), Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Internal Medicine, St Vinzenz Hospital, Zams, Austria.
- Department of Internal Medicine, County Hospital Kufstein, Kufstein, Austria.
ORCID-Profile: Christine Brunner, Christian Marth, Daniel Egle, Miriam Emmelheinz, Birgit Volgger, Sibylle Puntscher, Emanuel Bruckmoser
Zitieren
APA
Brunner, C., Arvandi, M., Marth, C., Egle, D., Baumgart, F., Emmelheinz, M., Walch, B., Lercher, J., Iannetti, C., Wöll, E., Pechlaner, A., Zabernigg, A., Volgger, B., Castellan, M., Andraschofsky, O. T., Markl, A., Hubalek, M., Schnallinger, M., Puntscher, S., …, & Laimer, J. (2025). Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study. Journal of Clinical Oncology, 43(2), 180-188. https://doi.org/10.1200/jco.24.00171
Vancouver
Brunner C, Arvandi M, Marth C, Egle D, Baumgart F, Emmelheinz M, et al. Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study. Journal of Clinical Oncology. 2025;43(2):180-188. doi:10.1200/jco.24.00171
BibTeX
@article{Brunner2025,
author = {Brunner, Christine and Arvandi, Marjan and Marth, Christian and Egle, Daniel and Baumgart, Florentina and Emmelheinz, Miriam and Walch, Benjamin and Lercher, Johanna and Iannetti, Claudia and Wöll, Ewald and Pechlaner, Agnes and Zabernigg, August and Volgger, Birgit and Castellan, Maria and Andraschofsky, Oliver Tibor and Markl, Alice and Hubalek, Michael and Schnallinger, Michael and Puntscher, Sibylle and Siebert, Uwe and Schönherr, Sebastian and Forer, Lukas and Bruckmoser, Emanuel and Laimer, Johannes},
title = {Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {2},
pages = {180--188},
doi = {10.1200/jco.24.00171}
}
EUVIMED